-To compare the single dose bioavailability of Kali and BTG

-To compare the bioavailability of Oxandrolone 10mg tablets with that of OXANDRIN 10mg tablets following a single -dose in healthy, adult subjects under fasting conditions.

Inclusion Criteria:

• Healthy subject at least 18 years of age, may be male or they may be female who are unable to bear children.
• Each subject shall be given a general physical examination within 28days of the initiation study.
• At the end of the study, the subjects will have an exit evaluation consisting of interim history, global evaluation, and clinical laboratory measurements.
• Each female subject will be given a serum test as part of the pregnancy study screening process.
• Clinical laboratory measurements will include Hematology, Clinical Chemistry, Urine Analysis, HIV Screen,hepatitis-B, C screen and Drugs of abuse Screen

Exclusion Criteria:

• Subjects with a history of alcoholism or drug addiction(during past 2 years), or serious gastrointestinal, renal hepatic or cardiovascular disease, tuberculosis, epilepsy. asthma, diabetes, psychosis or glaucoma will not be eligible for thsi study.
• Subjects with any history of breast or prostate cancer will not be eligible to participate in this study.
• Subjects who have a history of allergic response to the class of drug being tested will be excluded from the study.
• Subjects found to have urine/saliva concentration of any of the tested drugs will not be allowed to participate.
• Subjects who have taken any investigational drug within thirty days prior to the first dosing of the study will not be allowed to participate.
• Female subjects who are not able to bear children will not be allowed to participate.
• Female subjects with positive or inconclusive results will be withdrawn from the study.